Leber先天性黃斑部生物模型（LCA）：市場展望、流行病學、競爭格局、市場預測報告，2026-2036年

市場概覽

• 德國生命週期評估市場預計將從 2026 年的 1.3 億美元成長到 2036 年的 2 億美元。
• 以下因素正在推動市場成長：
• 基因療法的廣泛應用和新型視網膜治療方法的出現。
• 基因診斷和疾病理解的進展
• 未來的發展取決於能夠維持或改善視覺功能的持續治療。

萊伯氏先天性黑蒙症的市場展望與預測

萊伯氏先天性黑蒙症概述

萊伯氏先天性黑蒙症 (LCA) 是一組遺傳性視網膜營養不良，由光感受器功能和視覺循環必需基因的突變引起。此病通常在嬰兒期表現為嚴重的視力障礙、眼球震顫和視覺反應減弱，但表現型和進展因基因型而異。治療方案包括視覺復健、低視力支持、教育服務和遺傳諮詢。 Luxturna 是一種獲得 FDA 批准用於治療 RPE65 雙等位基因突變引起的視網膜營養不良的藥物，它促成了針對特定亞組的基因增強療法的建立。目前的研究趨勢包括基因特異性和基因組編輯方法。 ATSN-101 正在研究用於治療 GUCY2D 相關 LCA，而 EDIT-101 則利用 CRISPR-Cas9 編輯技術治療導致 LCA10 的特定 CEP290 突變。基於 RNA 的策略在全球範圍內仍處於研究階段。主要挑戰包括遺傳異質性、視網膜變性、眼內給藥、療效持續時間以及在感光細胞顯著減少之前進行治療。

主要亮點

• 在美國，預計患有 LCA 的人數將從 2026 年的 59,596 人增加到 2036 年的 65,506 人。
• LCA 是一種罕見的遺傳性視網膜疾病，會導致兒童早期出現嚴重的視力障礙。
• 進行性視力喪失和有限的治療選擇造成了沉重的疾病負擔。
• 目前，維持或恢復視力的治療需求仍遠未滿足。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Opus Genetics, Inc.
• Spark Therapeutics, Inc.
• Ocugen
• Atsena Therapeutics Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 新興療法的關鍵未滿足需求和未來成就前景
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Leber Congenital Amaurosis Market Outlook and Forecast

Thelansis's "Leber Congenital Amaurosis (LCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leber Congenital Amaurosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Leber Congenital Amaurosis Overview

Leber congenital amaurosis (LCA) is a group of inherited retinal dystrophies caused by variants in genes essential for photoreceptor function and the visual cycle. It usually presents in infancy with severe visual impairment, nystagmus, and poor visual responses; phenotype and progression vary by genotype. Management includes visual rehabilitation, low-vision support, educational services, and genetic counseling. Voretigene neparvovec (Luxturna) is FDA-approved for biallelic RPE65 mutation-associated retinal dystrophy, establishing gene augmentation in a defined subgroup. The development landscape includes gene-specific and genome-editing approaches. ATSN-101 is being studied for GUCY2D-associated LCA, while EDIT-101 uses CRISPR-Cas9 editing for a specific CEP290 variant causing LCA10. RNA-based strategies remain investigational globally. Key challenges include genetic heterogeneity, retinal degeneration, ocular delivery, durability, and treatment before substantial photoreceptor loss.

Key Highlights

• In the United States, LCA prevalence cases are projected to increase from 59,596 in 2026 to 65,506 by 2036.
• LCA is a rare inherited retinal disorder causing severe visual impairment from early childhood.
• Progressive vision loss and limited treatment options create a significant disease burden.
• Significant unmet need remains for therapies that preserve or restore vision.

Market Overview

• The Germany LCA market is projected to grow from $130M in 2026 to $200M by 2036.
• Market growth is driven by:
• Increasing adoption of gene therapy and emerging retinal therapies
• Advances in genetic diagnosis and disease understanding
• Future growth will depend on durable treatments that preserve or improve visual function.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Opus Genetics, Inc.
• Spark Therapeutics, Inc.
• Ocugen
• Atsena Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)